Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study
Abstract
BACKGROUND: Ketamine rapidly reduces thoughts of suicide in patients with treatment-resistant depression who are at low risk for suicide. However, the extent to which ketamine reduces thoughts of suicide in depressed patients with current suicidal ideation remains unknown. METHODS: Between April 2012 and October 2013, 14 outpatients with DSM-IV-diagnosed major depressive disorder were recruited for the presence of current, stable (≥ 3 months) suicidal thoughts. They received open-label ketamine infusions over 3 weeks (0.5 mg/kg over 45 minutes for the first 3 infusions; 0.75 mg/kg over 45 minutes for the last 3). In this secondary analysis, the primary outcome measures of suicidal ideation (Columbia-Suicide Severity Rating Scale [C-SSRS] and the Suicide Item of the 28-item Hamilton Depression Rating Scale [HDRS₂₈-SI]) were assessed at 240 minutes postinfusion and for 3 months thereafter in a naturalistic follow-up. RESULTS: Over the course of the infusions (acute treatment phase), 7 of 14 patients (50%) showed remission of suicidal ideation on the C-SSRS Ideation scale (even among patients whose depression did not remit). There was a significant linear decrease in this score over time (P < .001), which approached significance even after controlling for severity of 6-item Hamilton Depression Rating Scale (HDRS₆) core depression items (P = .05). Similarly, there were significant decreases in the C-SSRS Intensity (P < .01) and HDRS₂₈-SI (P < .001) scores during the acute treatment phase. Two of the 7 patients who achieved remission during the acute treatment phase (29%) maintained their remission throughout a 3-month naturalistic follow-up. CONCLUSIONS: In this preliminary study, repeated doses of open-label ketamine rapidly and robustly decreased suicidal ideation in pharmacologically treated outpatients with treatment-resistant depression with stable suicidal thoughts; this decrease was maintained for at least 3 months following the final ketamine infusion in 2 patients. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01582945.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
About 50% of response to antidepressants can be attributed to genetic factors.
“as about 50% of response to antidepressants can be attributed to genetic factors. 622”
From Time for united action on depression: a Lancet–World Psychiatric Association Commission (2022) · cites this paper as [622]
Cites
Still being checked.
Cited by
Sorted by citations
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207 · see citing works
Time for united action on depression: a Lancet–World Psychiatric Association Commission
Herrman, H., Patel, V., Kieling, C., Berk, M., Buchweitz, C., Cuijpers, P., Furukawa, T. A., Kessler, R. C., Kohrt, B. A., Maj, M., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02141-3 · Cited by 1,104 · see citing works
Turecki, G., Brent, D. A., Gunnell, D., O’Connor, R. C., Oquendo, M. A., Pirkis, J., & Stanley, B. H. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0121-0 · Cited by 1,074 · see citing works
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696 · see citing works
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676 · see citing works
Grunebaum, M. F., Galfalvy, H. C., Choo, T.-H., Keilp, J. G., Moitra, V. K., Parris, M. S., Marver, J. E., Burke, A. K., Milak, M. S., Sublette, M. E., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17060647 · Cited by 431 · see citing works
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.09.071 · Cited by 408 · see citing works
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256 · see citing works
Suicide and Suicide Risk in Adolescents
Hua, L. L., Lee, J., Rahmandar, M. H., Sigel, E. J., COMMITTEE ON ADOLESCENCE, & COUNCIL ON INJURY, V. (2024) · Pediatrics · doi:10.1542/peds.2023-064800 · Cited by 205 · see citing works
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188 · see citing works
Ionescu, D. F., Bentley, K. H., Eikermann, M., Taylor, N., Akeju, O., Swee, M. B., Pavone, K. J., Petrie, S. R., Dording, C., Mischoulon, D., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.037 · Cited by 179 · see citing works
Self-citationAttenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174 · see citing works
Effects of <i>N</i>,<i>N</i>-Dimethyltryptamine on Rat Behaviors Relevant to Anxiety and Depression
Cameron, L. P., Benson, C. J., Dunlap, L. E., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00134 · Cited by 171 · see citing works
Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight
Singh, I., Morgan, C. J. A., Curran, V. H., Nutt, D., Schlag, A. K., & McShane, R. H. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30102-5 · Cited by 162 · see citing works
Kryst, J., Kawalec, P., Mitoraj, A. M., Pilc, A., Lasoń, W., & Brzostek, T. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00097-z · Cited by 159 · see citing works
Neuropathology of suicide: Recent findings and future directions
Lutz, P.-E., Mechawar, N., & Turecki, G. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.141 · Cited by 158 · see citing works
Phillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owoeye, O., Batten, L. A., & Blier, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0570-x · Cited by 139 · see citing works
History repeating: guidelines to address common problems in psychedelic science
van Elk, M., & Fried, E. I. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231198466 · Cited by 137 · see citing works
Depressive disorders: treatment failures and poor prognosis over the last 50 years
Blackburn, T. P. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.472 · Cited by 136 · see citing works
Xiong, J., Lipsitz, O., Chen-Li, D., Rosenblat, J. D., Rodrigues, N. B., Carvalho, I., Lui, L. M. W., Gill, H., Narsi, F., Mansur, R. B., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.12.038 · Cited by 124 · see citing works
Transient stimulation with psychoplastogens is sufficient to initiate neuronal growth
Ly, C., Greb, A. C., Vargas, M. V., Duim, W. C., Grodzki, A. C. G., Lein, P. J., & Olson, D. E. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00065 · Cited by 123 · see citing works
Ketamine as a rapid-acting agent for suicidal ideation: A meta-analysis
Bartoli, F., Riboldi, I., Crocamo, C., Brita, C. D., Clerici, M., & Carrà, G. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.010 · Cited by 113 · see citing works
McIntyre, R. S., Rodrigues, N. B., Lee, Y., Lipsitz, O., Subramaniapillai, M., Gill, H., Nasri, F., Majeed, A., Lui, L. M. W., Senyk, O., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.088 · Cited by 110 · see citing works
Critical appraisal of major depression with suicidal ideation
Pompili, M. (2019) · Annals of General Psychiatry · doi:10.1186/s12991-019-0232-8 · Cited by 100 · see citing works
Fukumoto, K., Iijima, M., Funakoshi, T., & Chaki, S. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx116 · Cited by 90 · see citing works
Amidfar, M., Woelfer, M., Réus, G. Z., Quevedo, J., Walter, M., & Kim, Y.-K. (2019) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2019.109668 · Cited by 86 · see citing works
Risks Associated with Misuse of Ketamine as a Rapid-Acting Antidepressant
Zhu, W., Ding, Z., Zhang, Y., Shi, J., Hashimoto, K., & Lu, L. (2016) · Neuroscience Bulletin · doi:10.1007/s12264-016-0081-2 · Cited by 80 · see citing works
Investigational drugs in recent clinical trials for treatment-resistant depression
Garay, R. P., Zarate, C. A., Charpeaud, T., Citrome, L., Correll, C. U., Hameg, A., & Llorca, P. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1283217 · Cited by 74 · see citing works
mGlu2/3 Receptor Antagonists as Novel Antidepressants
Chaki, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.008 · Cited by 73 · see citing works
THERAPEUTIC MECHANISMS OF KETAMINE
Mihaljević, S., Pavlović, M., Reine, K., & Čačić, M. (2020) · Psychiatria Danubina · doi:10.24869/psyd.2020.325 · Cited by 75 · see citing works
Siegel, A. N., Di Vincenzo, J. D., Brietzke, E., Gill, H., Rodrigues, N. B., Lui, L. M. W., Teopiz, K. M., Ng, J., Ho, R., McIntyre, R. S., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.03.009 · Cited by 70 · see citing works
Psychedelic‐inspired approaches for treating neurodegenerative disorders
Saeger, H. N., & Olson, D. E. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15544 · Cited by 65 · see citing works
Zhou, Y., Lan, X., Wang, C., Zhang, F., Liu, H., Fu, L., Li, W., Ye, Y., Hu, Z., Chao, Z., et al. (2023) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2023.05.031 · Cited by 59 · see citing works
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine
Browne, C. A., Falcón, E., Robinson, S. A., Berton, O., & Lucki, I. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx079 · Cited by 56 · see citing works
Grabski, M., Borissova, A., Marsh, B., Morgan, C. J. A., & Curran, H. V. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112629 · Cited by 55 · see citing works
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C. H., Li, X., Chaki, S., & Duman, R. S. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0705-0 · Cited by 55 · see citing works
Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study
Can, A., Hermens, D. F., Dutton, M., Gallay, C. C., Jensen, E., Jones, M., Scherman, J. K., Beaudequin, D. A., Yang, C., Schwenn, P., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01230-z · Cited by 53 · see citing works
Research on the pathophysiology, treatment, and prevention of suicide: practical and ethical issues
Nugent, A. C., Ballard, E. D., Park, L. T., & Zarate, C. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2301-6 · Cited by 45 · see citing works
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40 · see citing works
Beyond Ketamine: New Approaches to the Development of Safer Antidepressants
Chaki, S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x15666170221101054 · Cited by 40 · see citing works
Sinyor, M., Williams, M., Belo, S., Orser, B. A., Vincent, M., Mah, L., Zarate, C. A., Castel, S., LEVITT, A. J., & Schaffer, A. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.07.073 · Cited by 36 · see citing works
Scotton, E., Antqueviezc, B., Vasconcelos, M., Dalpiaz, G., Géa, L. P., Goularte, J. F., Colombo, R., & Rosa, A. R. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.114963 · Cited by 36 · see citing works
Ketamine for depression clinical issues
Iqbal, S., & Mathew, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.02.005 · Cited by 32 · see citing works
Safety of Repeated Administration of Parenteral Ketamine for Depression
Feifel, D., Dadiomov, D., & C. Lee, K. (2020) · Pharmaceuticals · doi:10.3390/ph13070151 · Cited by 31 · see citing works
Pharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30 · see citing works
History repeating: A roadmap to address common problems in psychedelic sciencePreprint
van Elk, M., & Fried, E. I. (2023) · doi:10.31234/osf.io/ak6gx · Cited by 30 · see citing works
mGlu receptors as potential targets for novel antidepressants
Chaki, S., & Fukumoto, K. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.02.001 · Cited by 30 · see citing works
Canuso, C. M., Singh, J. B., Fedgchin, M. M., Alphs, L. D., Lane, R., Lim, P., Pinter, C., Hough, D. W., Sanacora, G., Manji, H. K., et al. (2019) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.17105 · Cited by 28 · see citing works
Sales, A. J., Maciel, I. D. S., Suavinha, A. C. D. R., & Joca, S. R. L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02145-4 · Cited by 28 · see citing works
Ketamine vs midazolam: Mood improvement reduces suicidal ideation in depression
Hochschild, A., Keilp, J. G., Madden, S. P., Burke, A. K., Mann, J. J., & Grunebaum, M. F. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.12.055 · Cited by 25 · see citing works
Effects of somatic treatments on suicidal ideation and completed suicides
Hawkins, E. M., Coryell, W. H., Leung, S., Parikh, S. V., Weston, C. L., Nestadt, P. S., Nürnberger, J. I., Kaplin, A. I., Kumar, A., Farooqui, A. A., et al. (2021) · Brain and Behavior · doi:10.1002/brb3.2381 · Cited by 26 · see citing works
Wang, Y., Wang, X., Lan, L., Guo, Z., Kan, F., Hu, D., Gai, C., & Zhang, Y. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03605-1 · Cited by 24 · see citing works
Ahmed, G. K., Elserogy, Y., Elfadl, G. M. A., Abdelsalam, K. G., & Ali, M. A. S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.01.005 · Cited by 24 · see citing works
The Neuroscience of Suicidal Behavior
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205 · Cited by 22 · see citing works
A regulatory perspective on the evaluation of hallucinogen drugs for human use
Calderon, S. N., Hunt, J., & Klein, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.11.028 · Cited by 21 · see citing works
Chaki, S. (2019) · Advances in pharmacology · doi:10.1016/bs.apha.2019.03.004 · Cited by 21 · see citing works
Gallay, C. C., Forsyth, G., Can, A., Dutton, M., Jamieson, D., Jensen, E., Hermens, D. F., Bennett, M. R., & Lagopoulos, J. (2021) · Psychiatry Research Neuroimaging · doi:10.1016/j.pscychresns.2021.111369 · Cited by 20 · see citing works
Chan, L. F., Eu, C. L., Soh, S. Y., Maniam, T., Kadir, Z. S., Chong, B. T. W., Loo, J. L., Sharip, S., WONG, V. C. W., Loo, T. H., et al. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000316 · Cited by 19 · see citing works
Glutamine and New Pharmacological Targets to Treat Suicidal Ideation
Jiménez-Treviño, L., González-Blanco, L., Alvarez-Vázquez, C., Rodríguez-Revuelta, J., & Sáiz, P. A. (2020) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_168 · Cited by 19 · see citing works
Translating Interventional Neuroscience to Suicide: It’s About Time
Barredo, J., Bozzay, M. L., Primack, J. M., Schatten, H. T., Armey, M. F., Carpenter, L. L., & Philip, N. S. (2021) · Biological Psychiatry · doi:10.1016/j.biopsych.2021.01.013 · Cited by 19 · see citing works
Is Metabolism of (R)-Ketamine Essential for the Antidepressant Effects?
Chaki, S. (2017) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx120 · Cited by 17 · see citing works
Ketamine: A Review for Clinicians
Sanacora, G., & Katz, R. R. (2018) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.20180012 · Cited by 17 · see citing works
Danyeli, L. V., Şen, Z. D., Čolić, L., Kurzweil, L., Gensberger‐Reigl, S., Macharadze, T., Götting, F. N., Refisch, A., Liebe, T., Chand, T., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02346-0 · Cited by 16 · see citing works
Zhou, Y., Wang, C., Lan, X., Li, W., Chao, Z., Wu, K., McIntyre, R. S., & Ning, Y. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.779326 · Cited by 15 · see citing works
Wang, J. C. C., & Swainson, J. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001244 · Cited by 14 · see citing works
Tucciarone, J., Bandeira, I. D., Blasey, C. M., Kratter, I. H., Ehrie, J., Keller, J., Pankow, H., Chang, M., Hawkins, J., Evers, A. G., et al. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250840 · Cited by 13 · see citing works
(Es)Ketamine for Suicidal Ideation and Behavior: Clinical Efficacy
Alario, A. A., & Niciu, M. J. (2022) · Chronic Stress · doi:10.1177/24705470221128017 · Cited by 16 · see citing works
Browne, C. A., Wulf, H. A., Jacobson, M. L., Oyola, M. G., Wu, T. J., & Lucki, I. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113963 · Cited by 12 · see citing works
Clinical trials for rapid changes in suicidal ideation: lessons from ketamine
Ballard, E. D., Fields, J., Farmer, C. A., & Zarate, C. A. (2021) · Suicide and Life-Threatening Behavior · doi:10.1111/sltb.12663 · Cited by 10 · see citing works
Feng, W., Chen, C., Zeng, Y., & Zhang, B. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111152 · Cited by 9 · see citing works
Sakopoulos, S., & Todman, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146673 · Cited by 10 · see citing works
Kang, M. J. Y., Kulcar, E., Chandrasena, R. D., Anjum, M.-R., Fairbairn, J., Hawken, E. R., & Vázquez, G. H. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.113645 · Cited by 9 · see citing works
General Psychiatric Management for Suicidal Patients, With Remarks on Chronicity
Yager, J., & Feinstein, R. E. (2017) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000000701 · Cited by 9 · see citing works
Veraart, J. K. E., Smith-Apeldoorn, S. Y., Trueman, H., de Boer, M. K., Schoevers, R. A., & McShane, R. H. (2018) · BJPsych Open · doi:10.1192/bjo.2018.51 · Cited by 9 · see citing works
Ketamine Use for Suicidal Ideation in the General Hospital: Case Report and Short Review
Vulser, H., Vulser, C., RIEUTORD, M., Passeron, A., LEFEBVRE, D., BAUP, E., Seigneurie, A.-S., Thauvin, I., Limosin, F., & Lemogne, C. (2018) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000282 · Cited by 8 · see citing works
mGlu2/3 receptor as a novel target for rapid acting antidepressants
Chaki, S. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2020.04.001 · Cited by 8 · see citing works
Hahm, E. Y., Chamadia, S., Locascio, J. J., Pedemonte, J. C., Gitlin, J., Mekonnen, J., Ibala, R., Ethridge, B. R., Colon, K. M., Qu, J., et al. (2021) · PAIN Reports · doi:10.1097/pr9.0000000000000936 · Cited by 6 · see citing works
Self-citationEfficacy of ketamine versus esketamine in the treatment of perioperative depression: A review
Wen, W., Zhao, W., Xia, X., Duan, X., Zhang, L., Lin, D., Qi, Z., Wang, S., Gao, M., Liu, C., et al. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173773 · Cited by 8 · see citing works
A scientometric analysis of research on the role of NMDA receptor in the treatment of depression
Chen, X., Wang, X., Li, C., Zhang, Y., Feng, S., & Xu, S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1394730 · Cited by 7 · see citing works
Gonçalves, K. T. D. C., Tavares, V. D. D. O., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Arcoverde, E., SANTOS, R. G. D., Hallak, J. E. C., et al. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01925-6 · Cited by 7 · see citing works
Caldieraro, M. A., Tung, T. C., Baena, L. M. A., Vilapriño, M., Corral, R. M., de la Serna, L. D. A., Uribe, E. S., KANEVSKY, G. A., & Cabrera, P. (2022) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2022.06.002 · Cited by 6 · see citing works
Li, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5 · see citing works
Real-World Effectiveness of Repeated Ketamine Infusions for Treatment-Resistant Bipolar Depression
Fancy, F., Rodrigues, N. B., Vincenzo, J. D. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021022 · Cited by 5 · see citing works
Infusing Hope Into the Treatment of Suicidality: a Review of Ketamine’s Effects on Suicidality
Rengasamy, M. L., Hsiung, K. S., & Price, R. B. (2019) · Current Behavioral Neuroscience Reports · doi:10.1007/s40473-019-00184-3 · Cited by 5 · see citing works
Nikolova, Y. S., Ruocco, A. C., Felsky, D., Lange, S., Prévot, T. D., Vieira, É. L. M., Voineskos, D., Wardell, J. D., Blumberger, D. M., Clifford, K. P., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1455968 · Cited by 6 · see citing works
Anzolin, A. P., Goularte, J. F., Pinto, J. V., Belmonte-de-Abreu, P. S., Cruz, L. N., Cordova, V. H. S., Magalhães, L. S., Rosa, A. R., Ceresér, K. M. M., & Kauer‐Sant’Anna, M. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1147298 · Cited by 4 · see citing works
Suicidality in treatment resistant depression: perspective for ketamine use.
Jakuszkowiak‐Wojten, K., Gałuszko‐Węgielnik, M., Wilkowska, A., Słupski, J., Włodarczyk, A., Górska, N., Szarmach, J., Szałach, Ł. P., Wiglusz, M. S., Krysta, K., et al. (2019) · PubMed · Cited by 4 · see citing works
Mora, R., López, S. G., Villar, M., Palmer, R., & Perlado, B. R. (2016) · Psiquiatría Biológica · doi:10.1016/j.psiq.2016.11.002 · Cited by 4 · see citing works
Alphs, L. D., Fu, D., Williamson, D., Jamieson, C., Greist, J. H., Harrington, M. A., Lindenmayer, J., McCullumsmith, C. B., Sheehan, D. V., Shelton, R. C., et al. (2022) · PubMed Central · Cited by 3 · see citing works
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 3 · see citing works
Psychedelics: Safety and Efficacy
Miller, N. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22020134 · Cited by 3 · see citing works
Stress, Vulnerability, and Suicide
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.003 · Cited by 2 · see citing works
Ketamine as a Rapid Antidepressant
Cusin, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-97241-1_10 · Cited by 2 · see citing works
Self-citationOverview of ketamine for major depression: efficacy and effectiveness
Bahji, A., Vázquez, G. H., Brietzke, E. M., & Zarate, C. A. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-821033-8.00005-8 · Cited by 2 · see citing works
(2R,6R)-Hydroxynorketamine, A Metabolite of Ketamine: The Antidepressant Actions and the Mechanisms
Fukumoto, K., & Duman, R. S. (2021) · Contemporary clinical neuroscience · doi:10.1007/978-3-030-79790-4_2 · Cited by 1 · see citing works
Vieira, F., Caliman‐Fontes, A. T., Souza‐Marques, B., Faria-Guimarães, D., Lins-Silva, D. H., Santos‐Lima, C., Jesus‐Nunes, A. P., & Quarantini, L. C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116443 · Cited by 1 · see citing works
Managing the risk of suicide in people with treatment-resistant depression
Franz, P. J., & Alpert, J. E. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824067-0.00039-6 · Cited by 1 · see citing works
Self-citationKetamine for treatment resistant depression in individuals with eating disorders: a comparison study
Wassenaar, E., Blalock, D. V., Duffy, A., Riddle, M. C., O’Melia, A. M., Weeks, H., Mehler, P. S., & Rienecke, R. D. (2025) · Journal of Eating Disorders · doi:10.1186/s40337-025-01448-y · Cited by 1 · see citing works
Menon, T., Lu, A., Arulmozhi, A., Dri, C. E., Wong, S., Teopiz, K. M., Le, G. H., Lee, S. M. L., Weissman, C. R., & McIntyre, R. S. (2026) · Psychiatry Research · doi:10.1016/j.psychres.2026.117036 · Cited by 1 · see citing works
Ketamine for Depression in Serious Illness: Evidence, Safety, and Practical Approaches
Noufi, P. E., Borris, J. B., Chammas, D., McDermott, C. L., Ufere, N. N., Webb, J. A., & Shalev, D. (2026) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2026.04.604 · Cited by 1 · see citing works
- Authors
- Ionescu, D. F., Swee, M. B., Pavone, K. J., Taylor, N., Akeju, O., Baer, L., Nyer, M., Cassano, P., Mischoulon, D., Alpert, J. E., Brown, E. N., Nock, M. K., Fava, M., & Cusin, C.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- ORCID
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2016-05-10
- Volume
- 77
- Issue
- 06
- Pages
- e719-e725
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2346471661
- Cited by
- 126
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 7 · 2023: 12 · 2022: 10 · 2021: 13 · 2020: 16 · 2019: 12 · 2018: 29 · 2017: 15 · 2016: 2
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- ketamine, suicidal ideation, major depressive disorder, treatment-resistant depression, intravenous ketamine infusion, suicide prevention, remission maintenance, Columbia Suicide Severity Rating Scale, Hamilton Depression Rating Scale
- MeSH terms
- Adolescent, Adult, Aged, Major Depressive Disorder, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Ketamine, Male, Middle Aged, Psychiatric Status Rating Scales, Psychometrics, Remission Induction, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review